（经2023年11月30日公司五届十次董事会审议通过） 第一章 总则 第一条 为充分发挥重庆三圣实业股份有限公司(以下简称" 公司")独立董事在公司治理中的作用，强化对内部董事及经理层的 约束和激励机制，保护中小股东及利益相关者的利益，促进公司规范 运作，根据《中华人民共和国公司法》、《上市公司独立董事管理办法》 、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》以及本公司章程的有关规定，制定本工作制度。 第二条 公司董事会成员中应当至少包括三分之一独立董事， 独立董事中至少包括一名会计专业人士。 公司应当在董事会中设置审计委员会。审计委员会成员应当为 不在公司担任高级管理人员的董事，其中独立董事应当过半数，并 由独立董事中会计专业人士担任召集人。 独立董事应当在公司薪酬与考核委员会、提名委员会成员中过 半数，并担任召集人。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应 当按照法律、行政法规、中国证券监督管理委员会规定、证券交易 所业务规则和公司章程的规定，认真履行职责，在董事会中发挥参 与决策、监督制衡、专业咨询作用，维护公司整体利益，保护中小 股东合法权益。 第四条 为 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2023-88 号 重庆三圣实业股份有限公司 第五届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重庆三圣实业股份有限公司（以下简称"公司"）第五届董事会第十次会议 于 2023 年 11 月 30 日 10:30 在公司 1212 会议室以现场和通讯相结合的方式召 开，本次会议通知于 2023 年 11 月 27 日发出，会议应到董事 9 人，实到 9 人。 会议的召开符合《公司法》和《公司章程》的规定，会议表决合法有效。 会议由董事长严欢女士主持，会议经审议，表决通过如下议案： 一、通过《关于修订<公司章程>的议案》 根据《国务院办公厅关于上市公司独立董事制度改革的意见》（国办发〔2023〕 9 号）、《上市公司独立董事管理办法》（证监会令第 220 号）、《深圳证券交易所 股票上市规则》（深证上〔2023〕701 号）、《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》（深证上〔2023〕703 号）等法律、法 规和规范性文件的规定，为进一步完善公 ...

证券代码：002742 证券简称：ST三圣 公告编号：2023-87号 重庆三圣实业股份有限公司 关于参加重庆辖区 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步做好投资者关系管理，增强与广大投资者的互动交流，重庆三圣实 业股份有限公司（以下简称“公司”）将参加重庆上市公司协会联合深圳市全景 网络有限公司举办的“重庆辖区 2023年投资者网上集体接待日活动”。活动将于 2023年 11月17日（星期五）15:00-17:00 举行，投资者可以通过“全景路演” （http://rs.p5w.net）进入本公司互动平台参与互动交流。 届时，公司相关高级管理人员将参加本次活动，就投资者关心的问题，与投 资者进行“一对多”形式的在线沟通和交流。欢迎广大投资者积极参与! 特此公告 重庆三圣实业股份有限公司董事会 2023年11月10 日 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2023-86 号 重庆三圣实业股份有限公司 特此公告 重庆三圣实业股份有限公司董事会 | | 证批的批量，本品的批量为 300 万片/批。今后的商业化 | | --- | --- | | | 生产如需放大批量，请注意开展相应的放大研究及验证。 | | 上市许可持有人 | 名称：辽源市百康药业有限责任公司 | | | 地址：辽源经济开发区财富大路 2858 号 | | 生产企业 | 名称：辽源市百康药业有限责任公司 | | | 地址：辽源经济开发区财富大路 2858 号 | 二、该药品其他情况 该药品为苯海拉明的类似物，主要抑制咳嗽中枢而镇咳，也有微弱的抗组作 用，无依赖及耐受性。 三、对公司的影响及风险提示 百康药业产品盐酸氯哌丁片通过仿制药一致性评价有利于提升该药品的市 场竞争力，有利于该药品未来的市场拓展，同时为百康美药业后续产品开展一致 性评价工作积累了经验。但因受到国家政策、市场环境变化等因素的影响，该药 品销售具有较大不确定性，敬请广大投资者谨慎决策，注意投资风险。 关于全资子公司药品通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息 ...

Financial Performance - The company's revenue for Q3 2023 was ¥550,409,115.62, representing a 9.12% increase compared to the same period last year[5]. - The net profit attributable to shareholders was -¥34,044,325.66, a decrease of 15.59% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥25,404,277.35, down 45.05% from the previous year[5]. - The basic earnings per share for Q3 2023 was -¥0.0788, a decline of 15.63% year-on-year[5]. - Net profit for Q3 2023 was a loss of CNY 90,886,230.79, compared to a loss of CNY 55,880,894.31 in Q3 2022, reflecting a deterioration in profitability[19]. - The total comprehensive income for the third quarter was -87,460,347.59 CNY, compared to -44,755,229.26 CNY in the previous year[20]. - The net loss attributable to the parent company was -129,359,954.11 CNY, an increase from -74,164,420.35 CNY year-over-year[20]. - Basic and diluted earnings per share were both -0.3045 CNY, compared to -0.1877 CNY in the same period last year[20]. Cash Flow and Financial Stability - The operating cash flow net amount for the year-to-date was ¥34,982,532.74, reflecting a significant decrease of 70.69%[5]. - The company’s cash flow from operating activities remains a critical focus area for future financial stability and growth[19]. - Cash inflow from operating activities totaled 1,141,654,033.09 CNY, down from 1,257,391,594.33 CNY year-over-year[21]. - The net cash flow from operating activities was 34,982,532.74 CNY, significantly lower than 119,342,834.04 CNY in the previous year[21]. - Cash inflow from financing activities was 101,500,000.00 CNY, down from 260,100,000.00 CNY in the previous year[21]. - The net cash flow from financing activities was -24,902,047.66 CNY, compared to -20,276,097.36 CNY in the same period last year[21]. - The ending balance of cash and cash equivalents was 86,157,686.72 CNY, down from 114,776,733.00 CNY year-over-year[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,883,536,367.83, a decrease of 3.89% from the end of the previous year[5]. - Total liabilities decreased to CNY 2,998,732,147.82 from CNY 3,049,147,892.85, indicating a reduction in financial obligations[16]. - The equity attributable to shareholders decreased by 16.10% to ¥673,164,448.45 compared to the end of the previous year[5]. - The equity attributable to shareholders of the parent company fell to CNY 673,164,448.45 from CNY 802,312,531.40, showing a decline in shareholder value[16]. Financial Distress and Reorganization - The company is in the process of applying for reorganization due to an inability to repay due debts, indicating ongoing financial distress[12]. Operating Costs and Expenses - Total operating revenue for Q3 2023 reached CNY 1,615,643,024.88, an increase of 10.1% compared to CNY 1,467,246,893.56 in the same period last year[18]. - Total operating costs amounted to CNY 1,654,069,258.39, up 7.8% from CNY 1,534,085,417.69 year-on-year[18]. - The company reported a significant increase in financial expenses, totaling CNY 131,722,212.55, compared to CNY 104,218,790.88 in the previous year[18]. - Research and development expenses remained stable at CNY 12,398,845.42, slightly up from CNY 12,396,581.56 year-on-year[18]. Other Comprehensive Income - Other comprehensive income after tax for the period was CNY 3,425,883.20, down from CNY 11,125,665.05 in the same quarter last year[19].

证券代码：002742 证券简称：ST 三圣 公告编号：2023-85 号 重庆三圣实业股份有限公司 关于公司股票被实施其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、实行其他风险警示的主要原因 1、重庆三圣实业股份有限公司（以下简称"公司"）与控股股东控制的重 庆市碚圣医药科技股份有限公司（以下简称"碚圣医药"）共同向重庆市万盛区 恒辉小额贷款有限公司借款，并将该借款提供碚圣医药使用，该事项未经公司董 事会、监事会和股东大会审议，已经构成关联方资金占用。截至本公告日，资金 占用余额本息合计 8,015.92 万元。 2、公司海外子公司三圣药业有限公司于 2019 年 6 月 26 日与埃塞俄比亚 NIB 国际银行签订抵押担保合同，以其厂房和机器设备作为抵押物为 SSC Construction P.L.C（以下简称"SSC"）向埃塞俄比亚 NIB 国际银行借款 4 亿 比尔（折合人民币约 5,183 万元）提供担保，该事项未经公司董事会、监事会和 股东大会审议，已构成公司违规对外提供担保。截至本公告日，SSC 尚有人民币 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2023-83 号 重庆三圣实业股份有限公司 关于公司股票被实施其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、实行其他风险警示的主要原因 1、重庆三圣实业股份有限公司（以下简称"公司"）与控股股东控制的重 庆市碚圣医药科技股份有限公司（以下简称"碚圣医药"）共同向重庆市万盛区 恒辉小额贷款有限公司借款，并将该借款提供碚圣医药使用，该事项未经公司董 事会、监事会和股东大会审议，已经构成关联方资金占用。截至本公告日，资金 占用余额本息合计 7,922.77 万元。 2、公司海外子公司三圣药业有限公司于 2019 年 6 月 26 日与埃塞俄比亚 NIB 国际银行签订抵押担保合同，以其厂房和机器设备作为抵押物为 SSC Construction P.L.C（以下简称"SSC"）向埃塞俄比亚 NIB 国际银行借款 4 亿 比尔（折合人民币约 5,183 万元）提供担保，该事项未经公司董事会、监事会和 股东大会审议，已构成公司违规对外提供担保。截至本公告日，SSC 尚有人民币 ...

证券代码：002742 证券简称：ST 三圣 公告编号：2023-82 号 重庆三圣实业股份有限公司 关于公司股票被实施其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、实行其他风险警示的主要原因 1、重庆三圣实业股份有限公司（以下简称"公司"）与控股股东控制的重 庆市碚圣医药科技股份有限公司（以下简称"碚圣医药"）共同向重庆市万盛区 恒辉小额贷款有限公司借款，并将该借款提供碚圣医药使用，该事项未经公司董 事会、监事会和股东大会审议，已经构成关联方资金占用。截至本公告日，资金 占用余额本息合计 7,832.95 万元。 2、公司海外子公司三圣药业有限公司于 2019 年 6 月 26 日与埃塞俄比亚 NIB 国际银行签订抵押担保合同，以其厂房和机器设备作为抵押物为 SSC Construction P.L.C（以下简称"SSC"）向埃塞俄比亚 NIB 国际银行借款 4 亿 比尔（折合人民币约 5,183 万元）提供担保，该事项未经公司董事会、监事会和 股东大会审议，已构成公司违规对外提供担保。截至本公告日，SSC 尚有人民币 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥1,065,233,909.26, representing a 10.64% increase compared to ¥962,826,665.42 in the same period last year[23]. - The net profit attributable to shareholders of the listed company was -¥97,520,406.58, a decrease of 139.38% from -¥40,738,537.48 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥103,173,602.91, reflecting a 188.60% decline from -¥35,750,132.27 year-on-year[23]. - The basic earnings per share were -¥0.2257, down 139.34% from -¥0.0943 in the same period last year[23]. - The diluted earnings per share were also -¥0.2257, reflecting a 139.34% decrease compared to -¥0.0943 in the previous year[23]. - The weighted average return on net assets was -12.90%, a decline of 9.20% from -3.70% in the previous year[23]. - The company's revenue for the reporting period reached ¥1,065,233,909.26, representing a year-on-year increase of 10.64% compared to ¥962,826,665.42 in the same period last year[41]. - The cost of sales increased by 12.79% to ¥887,260,896.95 from ¥786,621,331.96, resulting in a slight decrease in gross margin[41]. - Research and development expenses decreased by 10.44% to ¥7,767,959.85 from ¥8,673,305.69, indicating a potential shift in focus or efficiency improvements[41]. - The pharmaceutical segment generated ¥474,577,423.77 in revenue, accounting for 44.55% of total revenue, with an 8.67% increase year-on-year[43]. - The construction materials and chemicals segment reported revenue of ¥566,176,572.25, which is 53.15% of total revenue, reflecting a 12.40% increase compared to the previous year[43]. Cash Flow and Assets - The net cash flow from operating activities was ¥61,216,586.23, slightly up by 0.42% from ¥60,959,395.02 in the previous year[23]. - The company's cash and cash equivalents increased by ¥22,964,348.99, although this represents a 19.44% decrease from the previous year[41]. - The company's total assets included ¥1,111,903,779.68 in accounts receivable, which accounted for 27.58% of total assets, up from 26.37% the previous year[47]. - The company's fixed assets decreased to ¥923,952,072.37, representing 22.92% of total assets, down from 24.15%[47]. - The total assets at the end of the reporting period were ¥4,031,342,944.20, a decrease of 0.23% from ¥4,040,800,589.29 at the end of the previous year[23]. - The owner's equity decreased to CNY 912,046,384.51 from CNY 991,652,696.44, representing a decline of 8.0%[139]. Business Segments - The company operates in two main business segments: building materials and pharmaceuticals, with significant products including concrete, water-reducing agents, and pharmaceutical intermediates[31]. - The building materials segment has seen a decline in supply chain performance due to rapidly shrinking market demand, despite strong positioning in Ethiopia under the "Belt and Road" initiative[31]. - The pharmaceutical segment includes over 20 types of raw materials and more than 80 formulations, with key products like paracetamol and chlorpheniramine being essential for clinical use[32]. - The company has established a strong market position in the pharmaceutical intermediates sector, with leading products such as chloramphenicol intermediates and procaine hydrochloride intermediates[37]. Risk Management and Strategy - The company faces risks from macroeconomic fluctuations, particularly in the construction materials sector, which is heavily influenced by national fixed asset investment and real estate investment[59]. - The company plans to mitigate risks by diversifying its business and expanding into international markets, particularly in Africa[60]. - Raw material costs account for over 70% of the total costs, making the company vulnerable to price fluctuations in raw materials[60]. - The company aims to enhance its cost advantages through technological innovation and refined management practices[60]. - The company is currently facing significant liquidity pressure, with tight working capital management being a priority[61]. - Strategies to alleviate financial pressure include improving accounts receivable turnover and optimizing inventory management[61]. Environmental Compliance - The company complies with various environmental protection laws and regulations, ensuring adherence to industry standards[69]. - The company has valid pollution discharge permits for its facilities, with specific expiration dates[70]. - The total discharge of chemical oxygen demand (COD) was maintained below the standard of 500 mg/L, with a reported level of 40 mg/L[72]. - The ammonia nitrogen discharge was recorded at 15 mg/L, which is below the national standard of 1 mg/L[72]. - The company has implemented new wastewater treatment technologies, resulting in a reduction of total phosphorus discharge to 4 mg/L, significantly below the standard[72]. - The company emphasizes environmental protection, conducting weekly inspections and maintenance of pollution control facilities to ensure normal operation and compliance[74]. Corporate Governance - The company has a well-established management team with decades of industry experience, enabling effective response to market dynamics and operational challenges[36]. - The company has undergone significant changes in its board of directors and management team in 2023[65]. - The company has held two shareholder meetings with participation rates of 29.67% and 33.95% respectively[64]. - The company is actively seeking strategic investors to support operational and strategic planning[61]. Future Outlook - The future outlook remains positive, with projected revenue growth of 15% for the next fiscal year based on current market trends[72]. - The company plans to expand its market presence by increasing production capacity in response to growing demand[72]. - The company has set a performance guidance for the next half of the year, aiming for a revenue growth of approximately 10%[163]. - The company plans to enhance its market expansion strategies, focusing on new product development and technological innovation in the upcoming quarters[163].

证券代码：002742 证券简称：ST 三圣 公告编号：2023-81 号 重庆三圣实业股份有限公司 关于审计监察部负责人辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《公司法》、《深圳证券交易所上市公司自律监管指引第 1 号——主板 上市公司规范运作》、《公司章程》等相关规定，陈小涵女士辞去公司审计监察 部负责人职务不会对公司日常经营产生不利影响，公司董事会将按照相关规定尽 快聘任新的审计监察部负责人。 截至本公告日，陈小涵女士未持有公司股份。公司董事会向陈小涵女士对公 司发展所做出的贡献表示衷心感谢！ 特此公告 重庆三圣实业股份有限公司董事会 2023 年 8 月 29 日 重庆三圣实业股份有限公司（以下简称"公司"）董事会于今日收到公司审 计监察部负责人陈小涵女士递交的书面辞职申请。陈小涵女士因个人原因，申请 辞去公司审计监察部负责人的职务，上述辞职申请自送达公司董事会之日起生效。 陈小涵女士辞去公司审计监察部负责人职务后，不再担任公司其他职务。 ...